

This is a repository copy of *The crystal structure of Rv2991 from Mycobacterium tuberculosis : An F 420 binding protein with unknown function.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/147627/>

Version: Accepted Version

---

**Article:**

Benini, Stefano, Haouz, Ahmed, Proux, Florence et al. (2 more authors) (2019) The crystal structure of Rv2991 from Mycobacterium tuberculosis : An F 420 binding protein with unknown function. JOURNAL OF STRUCTURAL BIOLOGY. pp. 216-224. ISSN 1047-8477

<https://doi.org/10.1016/j.jsb.2019.03.006>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# The crystal structure of Rv2991 from *Mycobacterium tuberculosis*: An F<sub>420</sub> binding protein with unknown function

Stefano Benini<sup>a,\*</sup>  
stefano.benini@unibz.it

Ahmed Haouz<sup>b</sup>

Florence Proux<sup>b, 1</sup>

Pedro Alzari<sup>c</sup>

Keith Wilson<sup>d</sup>

<sup>a</sup>Bioorganic Chemistry and Bio-Crystallography Laboratory (B<sub>2</sub>Cl), Faculty of Science and Technology, Free University of Bolzano, Piazza Università 5, Bolzano 39100, Italy

<sup>b</sup>C2RT-Plateforme de cristallographie, Institut Pasteur, CNRS UMR 3528, 75724 Paris Cedex 15, France

<sup>c</sup>Unité de Microbiologie Structurale, Institut Pasteur, CNRS UMR 3528, Université Paris Diderot, Sorbonne Paris Cité, 75724 Paris Cedex 15, France

<sup>d</sup>York Structural Biology Laboratory, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK

\*Corresponding author.

<sup>1</sup>Present address: Institut de Biologie (IBENS), Section Génomique Fonctionnelle, École normale supérieure, 46 Rue d’Ulm, Paris, 75005, France.

## Abstract

The crystal structure of the conserved hypothetical protein Rv2991 from *Mycobacterium tuberculosis* has been solved by SAD using seleno-methionine substituted protein. The dimeric biological assembly and the sequence and fold conservation are typical of F<sub>420</sub> cofactor binding enzymes. Despite Rv2991 still being of unknown function, sequence and structural comparison with similar proteins enable a role to be proposed for its C-terminal stretch of residues in recognizing and orienting the substrate. In addition, the C-terminus is involved in both protein folding and determining the size of the active site cavity.

**Keywords:** Structural genomics; *Mycobacterium tuberculosis*; F<sub>420</sub>; Unknown function; FDOR

## 1 Introduction

A wide range of redox reactions is catalyzed by enzymes containing flavin cofactors such as flavin mononucleotide, flavin adenine dinucleotide and the deazaflavin cofactor F<sub>420</sub> (Hemmerich et al., 1970; Daniels et al., 1985; Daniels et al., 1985). While the F<sub>420</sub> cofactor is not present in humans, F<sub>420</sub> binding proteins are particularly abundant in the pathogenic bacterium *Mycobacterium tuberculosis*. F<sub>420</sub> binding proteins are absent in the human gut flora (Selengut and Haft, 2010), and since many still do not have a function assigned, they present an interesting area of research as potential drug targets. For instance, the F<sub>420</sub> binding deazaflavin-dependent nitroreductase Rv3547 was shown to activate the bicyclic nitroimidazole pro-drug candidate PA-824 by promoting release of toxic NO into nonreplicating *M. tuberculosis* cells (Singh et al., 2008). The crystal structure of Rv3547 (Cellitti et al., 2012), has underlined the importance of investigating F<sub>420</sub> binding enzymes to identify their substrates and mode of action in order to design new drugs to control tuberculosis.

F<sub>420</sub> dependent split  $\beta$ -barrel enzymes have been classified as part of the large superfamily of flavin/deazaflavin oxidoreductases (FDORs), which includes proteins able to bind flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), and haem cofactors (Ahmed et al., 2015). Using sequence similarity networks, Ahmed et al., further divided the two previously determined major clades FDOR-A and FDOR-B (Taylor et al., 2010), into 22 subclades (FDORs A1-A4, AA1-AA6, B1-B12) with Rv2991 belonging to the FDOR-B1 group (Ahmed et al., 2015). In the same work the affinity of Rv2991 for the F<sub>420</sub> cofactor was determined with a  $K_d$  value of  $7.8 \pm 0.9 \mu\text{M}$  (with a  $K_d$  for FMN of  $27.9 \pm 4.3 \mu\text{M}$  and for FAD of  $26.4 \pm 1.4 \mu\text{M}$ ) confirming its cofactor specificity.

Rv2991 was selected as a target of the EU structural genomics project X-TB for its putative involvement in antibiotic resistance. Rv2991 is homologous to reductases in *Bacteroides fragilis* that confer resistance to 5-nitroimidazole antibiotics by reducing their nitro group to a nontoxic amine (Carlier et al., 1997; Manjunatha et al., 2006; Manjunatha et al., 2006). We solved the structure of Rv2991 by SAD and deposited it in the PDB in 2003. Unfortunately, to date no information is available on the role and function of this enzyme in *M. tuberculosis*. Here, we report the crystal structure, the sequence and structure similarity and the gene conservation amongst *Mycobacterium* spp. of Rv2991.

## 2 Materials and methods

### 2.1 Cloning, protein expression and purification

The Rv2991 coding sequence was amplified by a two-step PCR procedure from *M. tuberculosis* H37Rv (Cole et al., 1998) genomic DNA using primers containing the attB sites of the Gateway recombination system (Invitrogen). In the first step, the Rv2991 gene was amplified by PCR using the high fidelity *Pfx* DNA polymerase (Invitrogen), in presence of 5X enhancer solution for GC-rich templates, and both specific forward and reverse primers (Table 1). A DNA sequence encoding the TEV protease cleavage site was attached at the 5' end of the gene. In the second step, generic forward and reverse primers were used and the first PCR product served as template (Table 1). The final PCR product was visualized on an agarose gel, and purified (PCR purification kit, Qiagen). The expression clone was assembled in the Gateway recombination cloning system using the 'one-tube' protocol following the supplier's instructions, except that all components were used at half of the recommended volume, using pDONR201 as a cloning vector and pDEST17 as a His<sub>6</sub>-expression vector (pDEST17-Rv2991). The plasmid was first propagated in *Escherichia coli* DH5α and the correctness of the insert was checked by DNA sequencing. The final protein construct contains a single M to G substitution at the N-terminus. The expression vector pDEST-Rv2991 was then transformed into competent *E. coli* BL21(DE3)pLysS cells. For protein expression, cells were grown in 500 ml of LB medium containing 100 µg/ml ampicillin and 25 µg/ml chloramphenicol. The culture was grown for ≈3.5 h at 30 °C and when the OD<sub>600</sub> reached 0.8-0.9 induced with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG). After 1.5 hr of growth, cells were harvested by centrifugation, washed twice in 50 mM Tris-HCl buffer containing 150 mM NaCl and 10 mM imidazole, pH 8.0 (buffer A) and frozen. The cell pellet was thawed, and the cells lysed using a French press at 14,000 psi. After centrifugation, the supernatant was loaded onto a chromatographic column packed with 1 ml Ni-NTA resin (Qiagen) and previously equilibrated with buffer A. A linear gradient was developed from 20 mM imidazole to 500 mM at 0.5 ml min<sup>-1</sup> flow rate in 20 column volumes, with the Rv2991 eluting in a sharp peak at 120 mM imidazole. The fractions containing Rv2991 were pooled and diluted to 0.5 mg/ml with 50 mM Tris-HCl buffer containing 0.1 M NaCl and 1 mM β -mercaptoethanol, pH 8.0. The protein solution was incubated with His<sub>6</sub>-tagged rTEV protease (Invitrogen) at a 1:7 protein to rTEV ratio (w/w) for 6 hr at 30 °C. The solution was centrifuged to remove the aggregated cleaved His-tags and the supernatant loaded onto Ni-NTA resin, equilibrated as described above, to remove uncleaved Rv2991 and rTEV. The flow through, containing the tag-free protein was collected, concentrated to 5 ml volume and loaded onto a gel filtration Superdex 75 26/60 (GE Healthcare) previously equilibrated with 20 mM Tris-HCl + 150 mM NaCl pH 8.0 at a flow rate of 1 ml min<sup>-1</sup>. After gel filtration, the pure protein, which contains a single Met-Gly substitution at the N-terminus as a consequence of the cloning procedure, was concentrated to 10 mg/ml for crystallisation.

**Table 1** Gene cloning information.

Source organism	<i>Mycobacterium tuberculosis</i> (strain: H37Rv)
DNA source	Cosmid
Forward primer*	<u>CCTGTATTTTCAGGGCGGAACCAACAGCGCGCC</u>
Reverse primer*	<b>GTACAAGAAAGCTGGGTTTACGGGGCGGTCGAGCCACC</b>
Forward primer#	<b>GGGGACAAGTTTGTACAAAAAGCAGGCTCG</b> <u>GAAACCTGTATTTTCAGGGC</u>
Reverse primer#	<b>GGGGACCACTTTGTACAAGAAAGAAAGCTGGGT</b>
Cloning vector	pDONR201
Expression vector	pDEST17-Rv2991
Expression host	<i>E. coli</i> BL21(DE3) pLysS cells

The attB recombination sites are in bold, underlined is the rTEV cleavage site.

\* denotes primers used in the first PCR step.

# denotes primers used in the second PCR step.

The selenomethionine (SeMet)-labeled protein was produced in BL21(DE3) *E. coli* cells according to published protocols (Van Duyne et al., 1993) and purified as the native Rv2991 following the protocol described above.

## 2.2 Protein crystallization

Crystallization experiments were performed immediately after protein purification. Vapor diffusion sitting drop crystallization screens were performed at 290 K in 96 well Greiner plates using a CARTESIAN crystallisation robot. The screens used were: Crystal screen 1 and 2 (Hampton Research), Clear strategy screen CSS1 and CSS2 (Molecular Dimensions) and JBS 1 to 8 (Jena Bioscience). Reservoir solutions were 150 µl in volume and crystallization drops were composed of 200 nl of protein and 200 nl of reservoir solution. The crystallization plates were sealed with Crystalclear tape from Hampton Research and stored at 290 K.

To increase the size and the quality of the crystals the initial conditions were reproduced and refined by hand using vapor diffusion hanging drop in Linbro plates. Crystallization drops were made by mixing 2 µl of 12 mg/ml protein solution and 1 µl of the reservoir solution containing 25%(w/v) PEG 4000, 0.1 M tris HCl pH 8.5, 10 mM MgCl<sub>2</sub>, 200 mM sodium acetate, and 25% (v/v) ethylene glycol. Crystals grew within a week at 290 K with dimensions of 0.1 mm × 0.1 mm × 0.5 mm.

Selenomethionine-substituted protein concentrated to 11.2 mg/ml was crystallized using the hanging drop method by mixing 1 µl of protein with 1 µl of reservoir solution containing 30%(w/v) PEG 4000, 0.1 M Tris HCl pH 8.5, 20 mM magnesium acetate. Drops were equilibrated against 500 µl reservoir solution.

## 2.3 Data collection and processing

Data were collected for a crystal of the SeMet variant vitrified at 100 K with the mother liquor supplemented with 25% (v/v) of glycerol. As radiation damage was likely, the wavelength was fixed at the *K* edge absorption peak (0.979 Å), in order to maximize the anomalous scattering factors (Se theoretical values: *f* 3.84 and *f* −8.32, according to: [http://skuld.bmsc.washington.edu/scatter/AS\\_periodic.html](http://skuld.bmsc.washington.edu/scatter/AS_periodic.html)), to collect a SAD dataset (Gonzalez et al., 1999). Data were indexed and integrated using DENZO (Otwinowski and Minor. 1997) and scaled using SCALEPACK (Otwinowski et al., 2003) (Table 2).

Table 2 Data collection, processing and phasing statistics. Values for the outer shell are given in parentheses.	
Diffraction source	ESRF beamline ID29
Wavelength (Å)	0.979
Temperature (K)	100
Detector	ADSC quantum 210 CCD
Crystal-detector distance (mm)	230
Rotation range per image (°)	1
Total rotation range (°)	180
Exposure time per image (s)	1
Space group	<i>P</i> 4 <sub>3</sub> 22
<i>a</i> , <i>b</i> , <i>c</i> (Å)	49.31, 49.31, 132.59
α, β, γ (°)	90, 90, 90
Mosaicity (°)	1.53
Resolution range (Å)	49.39–2.0 (2.03–2.0)
Total No. of reflections	127,485 (2394)
No. of unique reflections	11,425 (921)
Completeness (%)	98.8 (76.7)
Redundancy	11.16 (2.6)
⟨ <i>I</i> /σ( <i>I</i> ) ⟩	11.68 (1.23#)

$R_{\text{r.i.m.}}^{\dagger}$	0.186 (1.007)
Overall $B$ factor from Wilson plot (Å <sup>2</sup> )	24.4
Phasing statics	46.22–2.30 (Å)
Phasing power (ano)	1.492
R-Cullis for acentric reflexions	0.707
FOM acentric/centric reflexions	0.361/0.043
FOM after DM	0.63

\* This shell was included as 46% of the reflections had  $I/\sigma(I)$  above 2. In the shell 2.15–2.11 the average  $I/\sigma(I)$  was 2.25 and in the shell 2.11–2.07 the average  $I/\sigma(I)$  was 1.77.

† Estimated  $R_{\text{r.i.m.}} = R_{\text{merge}}[N/(N - 1)]^{1/2}$ , where  $N$ = data multiplicity.

## 2.4 Structure solution and refinement

The positions of the Se-atoms were determined using SHELXD ([Schneider and Sheldrick, 2002](#)) and phase improvement and solvent flattening were carried out using SHARP ([Bricogne et al., 2003](#)). Phasing statistics are provided in [Table 2](#). Density modification confirmed the space group to be  $P4_322$  and the improved map was used for automatic model building using ARP/wARP ([Morris et al., 2004](#)) using Hendrickson Lattman coefficients during the first cycles of refinement as experimental phase information. Model inspection and final manual model building were done with COOT ([Emsley and Cowtan, 2004](#)), and refinement with REFMAC5 ([Vagin et al., 2004](#)). Structure solution and refined model parameters are provided in [Table 3](#).


Resolution range (Å)		49.39–2.00 (2.056–2.004)
Completeness (%)		97.3
No. of reflections, working set		10,829 (611)
No. of reflections, test set		542 (34)
Final $R_{\text{cryst}}$		0.202 (0.23)
Final $R_{\text{free}}$		0.281 (0.301)
No. of non-H atoms		
Protein		1237
Ligand		0
Water		125
Total		1362
R.M.S. deviations		
Bonds (Å)		0.020
Angles (°)		1.689
Average $B$ factors (Å <sup>2</sup> )		
Protein		28.7
Water		37.3
Ramachandran plot		



5JAB	0.51	14.1	11.2	1.72	127	117	2	<b>24</b>	82
3U5W	0.49	10.4	9.6	1.84	126	117	4	16	91
4ZKY	0.47	13.4	10.9	1.63	139	116	4	22	91
2HQ9	0.45	10.8	9.8	1.75	138	116	4	22	91
1VL7	0.45	7.2	8.7	1.89	135	116	6	18	82
2RE7	0.44	11.2	10.5	1.7	132	111	6	19	91
3F7E	0.42	8.9	9.1	2.32	126	116	6	17	82

The Q-score represents the quality function of Ca-alignment, it takes both the alignment length and RMSD into account (Krissinel and Henrick, 2004). 2HTI, flavin-nucleotide-binding protein bh\_0577 from *Bacillus halodurans* (JCSG to be published); 3DB0, putative pyridoxamine 5'-phosphate oxidase NP\_472219.1 from *Listeria innocua* (JCSG to be published); 5JAB, biliverdin reductase Rv2074 from *M. tuberculosis* in complex with F<sub>420</sub> (Ahmed et al., 2016); 3U5W uncharacterized protein from *Brucella melitensis* (SSGCID to be published); 4ZKY, F<sub>420</sub> binding protein, MSMEG\_6526, from *Mycobacterium smegmatis* (Ahmed et al., 2015); 2HQ9, hypothetical protein (NP\_107146.1) from *Mesorhizobium loti* (JCSG to be published); 1VL7, putative heme oxygenase (alr5027) from *Nostoc* sp. pcc 7120 (JCSG to be published); 2RE7, General Stress Protein COG3871 (YP\_263493.1) from *Psychrobacter arcticus* 273-4 (JCSG to be published); 3F7E, MSMEG\_3380 F<sub>420</sub> reductase (to be published). Nres represents the number of residues of the target structure, Nalign represents the number of aligned residues between target and query (Rv2991), Gaps represents the gaps in the structural alignment, SI% represents the sequence identity in percentage and SSeQ% the percentage of secondary structural elements of the query (Rv2991) that match the target structure.

The sequence alignment of Rv2991 and Rv2074 is shown in Fig. 2. Such high sequence identity was not found by the sequence similarity search by BLASTp when Rv2991 was compared to the whole PDB. In that search the highest similarity found was with 3F7E, *Mycobacterium smegmatis* Msmeg\_3380 F<sub>420</sub> reductase with a sequence coverage of only 63% and 34% sequence identity (resulting from the alignment of 37/108 residues), followed by 4QVB Rv1155 (Mashalidis et al., 2015; Canaan et al., 2005) with 42% query coverage and 33% sequence identity, and finally with 5BNC, MSMEG\_6519 (Ahmed et al., 2015) with a query coverage of 53% and 31% of sequence identity. The multiple alignment confirms a limited sequence conservation as shown in Fig. S1. The structural superposition of Rv2991 and Rv2074 using SSM (Krissinel and Henrick, 2004) reveals a very conserved structural core. The Rv2991 dimer is very similar to that of Rv2074 and suggests a conserved cofactor binding site. Fig. 2 (left panel) shows the structural superposition of Rv2991 and Rv2074 with its cofactor bound, their sequence alignment (bottom panel) and the conserved residues highlighted in Rv2991 cartoon representation.



**Fig. 2** The left panel shows a cartoon representation of the structural superposition of Rv2991 and Rv2074 with its cofactor bound (Rv2991 in cyan, Rv2074 in green and cofactor represented as sticks with oxygen red, carbon grey, nitrogen blue and phosphate orange), the right panel shows Rv2991 with highlighted the conserved residues in yellow. Chain A is in raspberry and chain B in cyan. Lower panel Rv2991 and Rv2074 sequence alignment.

The residues involved in cofactor binding are mostly conserved or the mutation does not affect binding (e.g., main chain atoms involved in H-bond formation). These are listed in [Table 5](#).


**Table 5** Residues involved in F420 cofactor binding in Rv2074 and the equivalent ones in Rv2991.

Rv2074	Rv2991
His36 Nε2	His38Nε2
Ala39 O	Ala41 O
Gly41 N	Trp43 N
Ile54 O	Glu54 O
Thr55 Oγ1	Thr55 Oγ1
Gln60 Oε1, Nε2	Gln60 Oε1, Nε2
Lys61N	Lys61N
Lys61Nζ	Lys61Nζ
Arg67 Nη1, Nη2	Arg67 Nη1, Nη2
Trp81 Nε1	Trp145 Nε1*
Arg9 Nη2	Arg6 Nη2?#

\* Structurally aligned residues.

# Not aligned but could change position upon cofactor binding.

Assuming that binding of the cofactor in Rv2991 is the same as in Rv2074 then the Rv2991 Trp43 (which replaces Gly41 in Rv2074, see [Table 5](#)) side chain lies at 90° to the deazaflavin ring system, a peculiarity that could be essential for the enzyme function. The last stretch of non-conserved residues includes α-helix 4 from Asp119 to Met129 and a short turn to connect to the antiparallel β-sheet 7 from Arg132, which contributes to the split β-barrel up to Asp146. The stretch of residues from His147 to Leu150 are part of a 3<sub>10</sub> helix while the end of the chain from Gly151 to Ala162 forms a long loop which folds back to bind to the other subunit ([Fig. 3](#)).




**Fig. 3** Ribbon representation of two views of Rv2991 showing the conserved C-terminal. The chain A is in raspberry and the chain B in cyan. The chain A C-terminal is colored in green and chain B C-terminal is colored in magenta. The cofactor superposed is from Rv2074 5JAB. The C-terminal secondary elements include α-helix 4 from Asp119 to Met129, the antiparallel β-sheet 7 from Arg132 to Asp146 and the 3<sub>10</sub> helix from His147 to Leu150.

The chain A conserved C-terminus from Gly158 to Ala162 establishes H-bonds with chain B α-helix 1 and α-helix 3 thus contributing to dimer stabilization. In detail, Gly158A O binds to Arg24B Nη1 (2.95 Å, α-helix 1), SerA160 N binds to GluB111 O (2.78 Å, α-helix 3), Thr161A Oγ1 simultaneously binds to ArgB112 O (2.76 Å, α-helix 3) and ArgB24 Nη1 (2.91 Å, α-helix 1). The conserved C-terminal of Rv2991 is a feature shared by all the 27 aligned protein



sequences with high identity as shown in the alignment of Fig. 4.




**Fig. 4** Multiple sequence alignment of the 27 selected sequences. Rv2991 and homologue from *Mycobacterium canettii*, *Mycobacterium oryzae*, *Mycobacterium kansasii*, *Mycobacterium marinum*, *Mycobacterium lacus*, *Mycobacterium haemophilum*,

*Mycobacterium shinjukuense*, *Mycobacterium asiaticum*, *Mycolicibacter heraklionensis*, *Mycolicibacter kumamotonensis*, *Mycobacterium shigaense*, *Mycobacterium sp. shizuoka-1*, *Mycolicibacter engbaekii*, *Mycolicibacterium sphagni*, *Mycolicibacterium insubricum*, *Mycolicibacterium confluentis*, *Mycolicibacterium fallax*, *Mycolicibacterium smegmatis*, *Mycolicibacterium aurum*, *Mycolicibacterium porcinum*, *Nocardia jejuensis*, *Nocardia niigatensis*, *Mycobacteroides salmoniphilum*, *Mycobacteroides franklinii*, *Williamsia limnetica*, *Mycolicibacterium gilvum*.


Arg24, Glu111 and Arg112 together with Thr161, are conserved in all the species considered.

The structural alignment of the structures selected by PDBeFold shows that, besides the conserved core involved in cofactor binding, the major differences are always in  $\alpha$ -helix 4 (from residue 119 to 129) and the C-terminal stretch of residues (from residue 147 to 162). We propose that  $\alpha$ -helix 4 and the stretch of residues from His147 to Gly158 are likely to be involved in substrate binding and specificity, regulating its entrance by direct interaction and steric hindrance possibly accommodating the compounds, in respect to the  $F_{420}$  cofactor, in a position as to allow the reaction to occur. Fig. 5 compares all the nine structures superposed on Rv2991 by SSM and grouped in Table 4.



**Fig. 5** Structural superposition between Rv2991 (1RFE, cyan) and the structures grouped in Table 4. 2HTI (salmon), flavin-nucleotide-binding protein bh\_0577 from *B. halodurans* (JCSG to be published), 3DB0 (dark purple), putative pyridoxamine 5'-phosphate oxidase NP\_472219.1 from *L. innocua* (JCSG to be published), 5JAB (yellow), biliverdin reductase Rv2074 from *M. tuberculosis* in complex with  $F_{420}$  (Ahmed et al., 2016), 3U5W (green), uncharacterized protein from *B. melitensis* (SSGCID to be published), 4ZKY (red),  $F_{420}$  binding protein, MSMEG\_6526, from *M. smegmatis* (Ahmed et al., 2015), 2HQ9 (grey) hypothetical protein (NP\_107146.1) from *M. loti* (JCSG to be published), 1VL7 (blue), putative heme oxygenase (alr5027) from *Nostoc sp. pcc 7120* (JCSG to be published), 2RE7 (light grey) General Stress Protein COG3871 (YP\_263493.1) from *P. arcticus* 273-4 (JCSG to be published), 3F7E (violet) MSMEG\_3380  $F_{420}$  reductase (to be published).

The electrostatic potential surface shows that a patch of negatively charged residues is located on the face opposite to the cofactor binding site. This patch is likely to be the site of interaction of a positively charged moiety of either another unknown protein or a ligand and could represent a putative allosteric regulation site. The left view of Fig. 6 shows the  $F_{420}$  cofactor (taken from Rv2074, 5JAB) bound to the binding groove while, the right view of Fig. 6, which is rotated of 180° along the vertical axis, shows that the  $F_{420}$  could be reached through a gap in the surface at the top of the negatively charged pocket.



**Fig. 6** The electrostatic potential surface generated by CCP4mg (McNicholas et al., 2011). Negative charges are in red while positive charges in blue. The left panel shows the surface on the side of the F<sub>420</sub> cofactor binding site. The right panel shows the protein rotated by 180° along the vertical axis. The cofactor superposed is from Rv2074 5JAB and is represented in ball and stick (carbon gray, nitrogen blue, oxygen red, phosphorous brown).

### 3.2 Conservation of Rv2991 in *Mycobacterium* spp.

The conservation of Rv2991 in *Mycobacterium* spp. has been analyzed as reported previously for the biliverdin reductase Rv2074 (Ahmed et al., 2016). Table 6 reports the results of a BLASTp search of the Rv2991 sequence against non-redundant databases compared to the results of Rv2074. An overall decreased presence of Rv2991 homologues is observed. Rv2991 is present in 25 out of the 38 (66%) species considered while Rv2074 is conserved in 30 out of 38 (79%). There is a drastic reduction of conservation amongst pathogenic strains, indeed Rv2991 homologues are only found in two (*M. tuberculosis* and *M. canettii*) out of the five pathogenic species (40%) in contrast with Rv2074 which is conserved in four out of five pathogenic species (80%).

**Table 6** Conservation of Rv2991 in *Mycobacterium* spp. in comparison with Rv2074 (list of genomes taken from (Ahmed et al., 2016)).

<i>Mycobacterium</i> species	Rv2074 homologue	Rv2991 homologue	Common habitat
<i>Pathogenic</i>			
<i>Mycobacterium tuberculosis</i>	Yes	Yes	Human infection
<i>Mycobacterium bovis</i>	Yes	No	Human/animal infection
<i>Mycobacterium africanum</i>	Yes	No	Human infection
<i>Mycobacterium canettii</i>	Yes	Yes	Human infection
<i>Mycobacterium leprae</i>	No	No	Human infection
<i>Opportunistic/commensal</i>			
<i>Mycobacterium abscessus</i>	Yes	Yes	Soil, water, infection
<i>Mycobacterium avium</i>	Yes	Yes	Water, soil, infection
<i>Mycobacterium intracellulare</i>	Yes	Yes	Water, soil, infection
<i>Mycobacterium marinum</i>	Yes	Yes	Water, soil, infection
<i>Mycobacterium kansasii</i>	Yes	Yes	Human infection
<i>Mycobacterium fortuitum</i>	Yes	Yes	Soil, water, infection
<i>Mycobacterium xenopi</i>	Yes	Yes	Soil, water, infection

<i>Mycobacterium neoaurum</i>	Yes	No	Soil, infection
<i>Mycobacterium ulcerans</i>	Yes	No	Water, soil, infection
<i>Mycobacterium chelonae</i>	Yes	Yes	Water, soil, infection
<i>Mycobacterium genavense</i>	Yes	Yes	Human infection
<i>Mycobacterium iranicum</i>	Yes	Yes	Human infection
<i>Mycobacterium yongonense</i>	Yes	No	Human infection
<i>Mycobacterium simiae</i>	Yes	Yes	Rhesus monkey
<i>Mycobacterium haemophilum</i>	Yes	Yes	Human infection
<i>Mycobacterium lepromatosis</i>	No	No	Human infection
<i>Mycobacterium setense</i>	Yes	Yes	Human infection
<i>Mycobacterium kyorinense</i>	No	Yes	Human infection
<i>Mycobacterium vulneris</i>	Yes	Yes	Human infection
<i>Mycobacterium celatum</i>	No	Yes	Human infection
<i>Rarely pathogenic/commensal</i>			
<i>Mycobacterium phlei</i>	Yes	Yes	Soil
<i>Mycobacterium smegmatis</i>	Yes	Yes	Soil
<i>Mycobacterium rhodesiae</i>	Yes	Yes	Soil
<i>Non-pathogenic</i>			
<i>Mycobacterium rutilum</i>	No	Yes	Soil
<i>Mycobacterium pallens</i>	No	No	Soil
<i>Mycobacterium crocinum</i>	No	No	Soil
<i>Mycobacterium rufum</i>	Yes	Yes	Soil
<i>Mycobacterium aromaticivorans</i>	Yes	No	Soil
<i>Mycobacterium indicus pranii</i>	Yes	No	Soil
<i>Mycobacterium bovis</i> (BCG vaccine)	No	No	Laboratory
<i>Mycobacterium vanbaalenii</i>	Yes	No	Mineral oil, soil
<i>Mycobacterium gilvum</i>	Yes	Yes	Water, soil
<i>Mycobacterium chubuense</i>	Yes	Yes	Soil

Rv2991 Overall 25/38 (66%), Pathogenic 2/5 (40%), Opportunistic/commensal 16/20 (80%), Rarely pathogenic/commensal 3/3 (100%), Non-pathogenic 4/10 (40%).

Rv2074 (no indent) Overall 30/38 (79%), Pathogenic 4/5 (80%), Opportunistic/commensal 17/20 (85%), Rarely pathogenic/commensal 3/3 (100%), Non-pathogenic 6/10 (60%).

## 4 Conclusions



Rv2991 is an F<sub>420</sub> cofactor binding enzyme with a split  $\beta$ -barrel typical of the flavin/deazaflavin oxidoreductase (FDORs) superfamily, with a highly-conserved cofactor binding region, but also with a divergent C-terminal possibly involved in substrate recognition and active site fold conservation. A patch of negatively charged residues is located on the face opposite to the cofactor binding site and we speculate that this could represent a putative allosteric regulation site. Compared to Rv2074, Rv2991 is less conserved across *Mycobacterium* spp., which hints at a redundant role of Rv2991 in the enzymatic pool of these organisms, confirming its non-essentiality for survival and pathogenicity of *M. tuberculosis* (Sasseti et al., 2001; Sasseti et al., 2003; Sasseti and Rubin, 2003). However, a role in antibiotic activation/resistance cannot be ruled out. Further *in vitro* investigations are required to identify its substrates and reaction products.

## Uncited reference

Schrodinger (2019).

## Acknowledgements

The work was supported by a grant from the 5<sup>th</sup> PCRDT program of the European Union (acronym X-TB). The authors thank the EU for support through the grant ‘Structural and Functional Genomics of Mycobacterium tuberculosis’ (QLK2-CT-2001-02018). We thank the staff of the recombinant protein platform at the Institut Pasteur for the production and purification of Rv2991. We are grateful to Dr. William Shepard for the assistance during the collection of diffraction data at beamline ID29 at the ESRF. Guy Dodson and Eleanor Dodson are acknowledged for the helpful discussions and contribution to the project during structure determination in 2003. SB thanks all the co-authors for their patience during manuscript preparation.

## Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jsb.2019.03.006>.

## References

- Ahmed F.H., Carr P.D., Lee B.M., Afriat-Jurnou L., Mohamed A.E., Hong N.S., Flanagan J., Taylor M.C., Greening C. and Jackson C.J., Sequence-structure-function classification of a catalytically diverse oxidoreductase superfamily in *Mycobacteria*, *J. Mol. Biol.* **427**, 2015, 3554–3571.
- Ahmed F.H., Mohamed A.E., Carr P.D., Lee B.M., Condić-Jurkić K., O'Mara M.L. and Jackson C.J., Rv2074 is a novel F<sub>420</sub> H<sub>2</sub>-dependent biliverdin reductase in *Mycobacterium tuberculosis*, *Protein Sci.* **25**, 2016, 1692–1709.
- Benini S., Chechik M., Ortiz Lombardia M., Polier S., Leech A., Shevtsov M.B. and Alonso J.C., The 1.58 Å resolution structure of the DNA-binding domain of bacteriophage SF6 small terminase provides new hints on DNA binding, *Acta Crystallogr Sect. F Struct. Biol. Cryst. Commun.* **69**, 2013, 376–381.
- Bricogne G., Vonrhein C., Flensburg C., Schiltz M. and Paciorek W., Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0, *Acta Crystallogr. D Biol. Crystallogr.* **59**, 2003, 2023–2030.
- Canaan S., Sulzenbacher G., Roig-Zamboni V., Scappuccini-Calvo L., Frassinetti F., Maurin D., Cambillau C. and Bourne Y., Crystal structure of the conserved hypothetical protein Rv1155 from *Mycobacterium tuberculosis*, *FEBS Lett.* **579**, 2005, 215–221.
- Carlier J.P., Sellier N., Rager M.N. and Reyssat G., Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of *Bacteroides fragilis*, *Antimicrob. Agents Chemother.* **41**, 1997, 1495–1499.
- Cellitti S.E., Shaffer J., Jones D.H., Mukherjee T., Gurumurthy M., Bursulaya B., Boshoff H.I., Choi I., Nayyar A., Lee Y.S., Cherian J., Niyomrattanakit P., Dick T., Manjunatha U.H., Barry C.E., 3rd, Spraggon G. and Geierstanger B.H., Structure of Ddn, the deazaflavin-dependent nitroreductase from *Mycobacterium tuberculosis* involved in bioreductive activation of PA-824, *Structure* **20**, 2012, 101–112.
- Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S., Barry C.E., 3rd, Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L., Oliver K., Osborne J., Quail M.A., Rajandream M.A., Rogers J., Rutter S., Seeger K., Skelton J., Squares R., Squares S., Sulston J.E., Taylor K., Whitehead S. and Barrell B.G., Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence, *Nature* **393**, 1998, 537–544.
- Daniels L., Bakhiet N. and Harmon K., Widespread distribution of a 5-deazaflavin cofactor in actinomyces and related bacteria, *System. Appl. Microbiol.* **6**, 1985, 12–17.

Emsley P. and Cowtan K., Coot: model-building tools for molecular graphics, *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2004, 2126-2132.

Gonzalez A., Pedelacq J., Sola M., Gomis-Ruth F.X., Coll M., Samama J. and Benini S., Two-wavelength MAD phasing: in search of the optimal choice of wavelengths, *Acta Crystallogr. D Biol. Crystallogr.* **55**, 1999, 1449-1458.

Hemmerich P., Nagelschneider G. and Veeger C., Chemistry and molecular biology of flavins and flavoproteins, *FEBS Lett.* **8**, 1970, 69-83.

Krissinel E. and Henrick K., Inference of macromolecular assemblies from crystalline state, *J. Mol. Biol.* **372**, 2007, 774-797.

Krissinel E. and Henrick K., Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions, *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2004, 2256-2268.

Manjunatha U.H., Boshoff H., Dowd C.S., Zhang L., Albert T.J., Norton J.E., Daniels L., Dick T., Pang S.S. and Barry C.E., 3rd, Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in *Mycobacterium tuberculosis*, *Proc. Natl. Acad. Sci. USA* **103**, 2006, 431-436.

Mashalidis E.H., Gittis A.G., Tomczak A., Abell C., Barry C.E., 3rd and Garboczi D.N., Molecular insights into the binding of coenzyme F<sub>420</sub> to the conserved protein Rv1155 from *Mycobacterium tuberculosis*, *Protein Sci.* **24**, 2015, 729-740.

McNicholas S., Potterton E., Wilson K.S. and Noble M.E., Presenting your structures: the CCP4mg molecular-graphics software, *Acta Crystallogr. D Biol. Crystallogr.* **67**, 2011, 386-394.

Morris R.J., Zwart P.H., Cohen S., Fernandez F.J., Kakaris M., Kirillova O., Vonnrhein C., Perrakis A. and Lamzin V.S., Breaking good resolutions with ARP/wARP, *J. Synchrotron Radiat.* **11**, 2004, 56-59.

Otwinowski Z. and Minor W., Processing of X-ray diffraction data collected in oscillation mode, In: Carter C.W. and Sweet R.M., (Eds.), *Macromolecular Crystallography Part A*, 1997, Elsevier, 307-326.

Otwinowski Z., Borek D., Majewski W. and Minor W., Multiparametric scaling of diffraction intensities, *Acta Crystallogr. A* **59**, 2003, 228-234.

Papadopoulos J.S. and Agarwala R., COBALT: constraint-based alignment tool for multiple protein sequences, *Bioinformatics* **23**, 2007, 1073-1079.

Potterton L., McNicholas S., Krissinel E., Gruber J., Cowtan K., Emsley P., Murshudov G.N., Cohen S., Perrakis A. and Noble M., Developments in the CCP4 molecular-graphics project, *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2004, 2288-2294.

Robert X. and Gouet P., Deciphering key features in protein structures with the new ENDscript server, *Nucl. Acids Res.* **42**, 2014, W320-W324.

Sassetti C.M., Boyd D.H. and Rubin E.J., Genes required for mycobacterial growth defined by high density mutagenesis, *Mol. Microbiol.* **48**, 2003, 77-84.

Sassetti C.M., Boyd D.H. and Rubin E.J., Comprehensive identification of conditionally essential genes in mycobacteria, *Proc. Natl. Acad. Sci. USA* **98**, 2001, 12712-12717.

Sassetti C.M. and Rubin E.J., Genetic requirements for mycobacterial survival during infection, *Proc. Natl. Acad. Sci. USA* **100**, 2003, 12989-12994.

Schneider T.R. and Sheldrick G.M., Substructure solution with SHELXD, *Acta Crystallogr. D Biol. Crystallogr.* **58**, 2002, 1772-1779.

Schrödinger, L., The PyMOL Molecular Graphics System, Version 2.2, Schrödinger, LLC.

Selengut J.D. and Haft D.H., Unexpected abundance of coenzyme F<sub>420</sub>-dependent enzymes in *Mycobacterium tuberculosis* and other actinobacteria, *J. Bacteriol.* **192**, 2010, 5788-5798.

Singh R., Manjunatha U., Boshoff H.I., Ha Y.H., Niyomrattanakit P., Ledwidge R., Dowd C.S., Lee I.Y., Kim P., Zhang L., Kang S., Keller T.H., Jiricek J. and Barry C.E., 3rd, PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release, *Science* **322**, 2008, 1392-1395.

Taylor M.C., Jackson C.J., Tattersall D.B., French N., Peat T.S., Newman J., Briggs L.J., Lapalikar G.V., Campbell P.M., Scott C., Russell R.J. and Oakeshott J.G., Identification and characterization of two families of F<sub>420</sub> H<sub>2</sub>-dependent reductases from *Mycobacteria* that catalyse aflatoxin degradation, *Mol. Microbiol.* **78**, 2010, 561-575.

Vagin A.A., Steiner R.A., Lebedev A.A., Potterton L., McNicholas S., Long F. and Murshudov G.N., REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use, *Acta Crystallographica Section D: Bio. Crystall.* **60**, 2004, 2184-2195.

Van Duyne G.D., Standaert R.F., Karplus P.A., Schreiber S.L. and Clardy J., Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin, *J. Mol. Biol.* **229**, 1993, 105–124.

Ye J., McGinnis S. and Madden T.L., BLAST: improvements for better sequence analysis, *Nucl. Acids Res.* **34**, 2006, W6–9.

## Appendix A. Supplementary material

The following are the Supplementary data to this article:


[Multimedia Component 1](#)

**Supplementary data 1**

[Multimedia Component 2](#)

**Supplementary data 2**

### Graphical abstract



---

### Highlights

- Rv2991 is an F<sub>420</sub> cofactor binding enzyme with a split  $\beta$ -barrel.
- Rv2991 shows a divergent C-terminal region possibly involved in substrate recognition.
- Rv2991 features a putative allosteric regulation site on the face opposite to F<sub>420</sub> binding pocket.
- Compared to Rv2074, Rv2991 is less conserved across *Mycobacterium* spp.

---

## Queries and Answers

**Query:** Your article is registered as a regular item and is being processed for inclusion in a regular issue of the journal. If this is NOT correct and your article belongs to a Special Issue/Collection please contact p.punniyaseelan@elsevier.com immediately prior to returning your corrections.

**Answer:** Yes

**Query:** The author names have been tagged as given names and surnames (surnames are highlighted in teal color). Please confirm if they have been identified correctly.

**Answer:** Yes

**Query:** This section comprises references that occur in the reference list but not in the body of the text. Please cite each reference in the text or, alternatively, delete it. Any reference not dealt with will be retained in this section.

**Answer:** this reference relates to the software PyMol used for the pictures, see section:

2.5 Sequence alignments and structural comparison

end of sentence: Figures representing the structures were prepared with CCP4mg (Potterton et al., 2004,McNicholas et al., 2011) or PyMol (Schrödinger).

**Query:** Have we correctly interpreted the following funding source(s) and country names you cited in your article: Institut Pasteur, France? /

**Answer:** Yes

**Query:** Note that the color shade has been removed in Table 6. Please check and correct if necessary.

**Answer:** color shade was not essential so better with white background, thank you for changing it